Effect of DPP-4 Inhibitors on the Cardiovascular System, Cancer and Pancreatitis.
10.4093/jkd.2013.14.3.138
- Author:
Eun Hee CHO
1
Author Information
1. Department of Internal Medicine, School of Medicine, Kangwon National University, Chuncheon, Korea. ehcho@kangwon.ac.kr
- Publication Type:Original Article
- Keywords:
Dipeptidyl-peptidase IV inhibitors;
Cardiovascular diseases;
Neoplasms;
Pancreatitis
- MeSH:
Animals;
Cardiovascular Diseases;
Cardiovascular System;
Dipeptidyl-Peptidase IV Inhibitors;
Hypoglycemia;
Pancreatitis
- From:Journal of Korean Diabetes
2013;14(3):138-142
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Recently, dipeptidylpeptidase-4 (DPP-4) inhibitors have been widely used as a second-line therapy for type 2 diabetes because of their glucose-lowering efficacy, weight neutral effects and minimal hypoglycemia. However, there have been concerns regarding the lack of evidence of the long-term consequences of DPP-4 inhibitors on cardiovascular disease, acute pancreatitis and cancers; therefore, the effects of DPP-4 inhibitors on these three major diseases are reviewed in this article. A growing body of evidence demonstrates the cardioprotective role of DPP-4 inhibitors in animal and small clinical studies. However, clearly conflicting data regarding the effects of DPP-4 inhibitors on cancers and pancreatitis have been presented in preclinical and epidemiologic studies. The forthcoming long-term clinical studies on cardiovascular safety will provide more conclusive answers relating to the safety of DPP-4 inhibitors, including their effects on cancer and pancreatitis.
